What is Umeclidinium?

Category: Prescription Drugs

Most popular types: Incruse Ellipta


Umeclidinium is a long-term, once-daily, maintenance treatment for patients with chronic obstructive pulmonary disease, chronic bronchitis, and/or emphysema.

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations Percentage
Severe 0
Moderate 1
Mild 0
None 6

Commonly reported side effects and conditions associated with Umeclidinium

Side effect Patients Percentage
Breathing difficulty 1
Chronic constipation 1


Based on patients currently taking Umeclidinium

Dosage Patients Percentage
62.5 mcg daily 6

Why patients stopped taking Umeclidinium

Multiple reasons could be selected

Reason Patients Percentage
Doctor's advice 1
See 1 patient who's stopped taking Umeclidinium


Currently taking Umeclidinium

Duration Patients Percentage
6 months - 1 year 1
1 - 2 years 2
2 - 5 years 3

Stopped taking Umeclidinium

Duration Patients Percentage
Less than 1 month 1
2 - 5 years 1
Adherence Evaluations Percentage
Always 2
Usually 5
Sometimes 0
Never taken as prescribed 0
Burden Evaluations Percentage
Very hard to take 0
Somewhat hard to take 1
A little hard to take 1
Not at all hard to take 5
Cost per month
Cost per month Evaluations Percentage
$200+ 0
$100-199 2
$50-99 0
$25-49 0
< $25 3
Not specified 2

What people switch to and from

Patients started taking Umeclidinium after stopping:

Treatment Patients Percentage
Tiotropium inhaler (Spiriva HandiHaler) 2
Aclidinium Bromide (Tudorza Pressair) 1
Budesonide-Formoterol (Symbicort) 1
Fluticasone-Salmeterol (Advair Diskus) 1
Ipratropium (Ipratropium Inhalant) 1

Show all 7 treatments patients report switching from

Patients stopped taking Umeclidinium and switched to:

Treatment Patients Percentage
Aclidinium Bromide (Tudorza Pressair) 1
Amoxicillin (Amoxil) 1
Budesonide-Formoterol (Symbicort) 1
Last updated:
There are no evaluations for Umeclidinium.